PeptideDB
en
EnglishEspañolDeutschPortuguês
PeptidesCategoriesCompareGuidesGlossary

Mazdutide

Extensively studied

Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes

Weight LossMetabolic

First-in-class dual GLP-1 and glucagon receptor agonist combining appetite suppression with thermogenesis stimulation.

Molecular & research data

Sequence
33-amino acid linear synthetic peptide
Molecular weight
4,563.1 Da
Half-life
6-8 days
Routes (research)
Injectable
Storage
Refrigerate reconstituted solution at 2-8°C, use within 30 days; lyophilized powder at -20°C until reconstitution

Overview

First-in-class dual GLP-1 and glucagon receptor agonist combining appetite suppression with thermogenesis stimulation. Phase 3 trials demonstrated superiority over semaglutide for weight loss and glycemic control.

Mechanism of action

Dual agonist activation: GLP-1 stimulates insulin, suppresses glucagon, slows gastric emptying; Glucagon increases energy expenditure and thermogenesis while GLP-1 counteracts glucose-raising effects.

Key research findings

  • Up to 20% body weight loss
  • Superior glycemic control versus semaglutide
  • Increased energy expenditure via glucagon receptor activation
  • Improved cardiometabolic markers (BP, lipids, liver fat)
  • Once-weekly injection convenience

Research applications

Weight Loss

  • Severe Obesity Management — GLORY-2 demonstrated 20.1% weight loss with 9mg over 60 weeks; 48.7% achieved ≥20% reduction.
  • Metabolic Syndrome Improvement — Significant reductions in waist circumference, systolic BP (-7.57 mmHg), triglycerides (-43%).
  • Liver Fat Reduction — Exploratory analysis showed 80.2% reduction in liver fat, suggesting MASLD/MASH benefits.

Type 2 Diabetes

  • Glycemic Control — HbA1c reductions of 1.41-2.03% across trials; DREAMS-3 showed -2.03% vs semaglutide -1.84%.
  • Dual Endpoint Achievement — 48% achieved HbA1c <7.0% AND ≥10% weight loss versus 21% with semaglutide.

Cardiovascular

  • Blood Pressure Reduction — Systolic reduction of -7.57 mmHg, diastolic -2.98 mmHg in clinical trials.
  • Lipid Profile Enhancement — Total cholesterol -16.82%, triglycerides -43.29%, LDL -17.07%.

Mazdutide FAQ

How much weight does mazdutide cause compared to semaglutide?+

Mazdutide demonstrated 20.1% weight loss over 60 weeks in Phase 3 trials (GLORY-2), with 48.7% of users achieving ≥20% reduction. This exceeded semaglutide's typical 12-17% losses. The dual GLP-1/glucagon mechanism accounts for superior weight loss and metabolic improvements.

Why does mazdutide cause thermogenesis while semaglutide doesn't?+

Mazdutide's glucagon receptor agonism increases energy expenditure and thermogenesis—burning calories actively rather than just reducing appetite. Semaglutide is GLP-1 only. This dual-agonist approach explains mazdutide's superior metabolic rate elevation.

Is mazdutide safer than semaglutide for nausea?+

Not necessarily. Both cause GLP-1-induced nausea early in treatment, though it typically improves with dose escalation. Mazdutide's additional heart rate increase (5-17 bpm) from glucagon agonism is a distinct side effect requiring cardiovascular monitoring.

Can I switch from semaglutide to mazdutide?+

Potentially, but with medical supervision. Both are GLP-1 agonists, so overlap during transition risks hypoglycemia and severe GI effects. Wait 1-2 weeks after stopping semaglutide before starting mazdutide, and monitor glucose carefully. Never combine them.

References

  1. [1]GLORY-1 Phase 3 TrialReference
  2. [2]GLORY-2 Phase 3 TrialReference
  3. [3]DREAMS-3 Phase 3 Trial - Head-to-Head vs SemaglutideReference
  4. [4]Phase 2 T2D TrialReference

Related peptides

Semaglutide

FDA-approved

FDA-approved GLP-1 receptor agonist

Semaglutide is an FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management, engineered with fatty-acid acylation for a once-weekly half-life.

Weight Loss

Tirzepatide

FDA-approved

FDA-approved dual GIP/GLP-1 receptor agonist

Tirzepatide is an FDA-approved dual GIP and GLP-1 receptor agonist for type 2 diabetes and weight management, producing larger average weight reduction than GLP-1-only agents in trials.

Weight Loss

BPC-157

Preclinical

Pentadecapeptide studied for tissue repair

BPC-157 is a synthetic 15-amino-acid peptide derived from a protein found in gastric juice, studied extensively in animal models for accelerated healing of tendon, ligament, muscle, and gut tissue.

Recovery & Healing

Last reviewed: 2026-06-26. Information is provided for research and educational reference only — see our disclaimer.